OMAR Opioid Use Disorder

Recruiting now · Phase 1

Conditions studied: Healthy Control, Opioid Use Disorder

In brief

The goal of this research study is to examine the endocannabinoid (eCB) function in vivo in individuals with opioid use disorder (OUD) by measuring cannabinoid receptor 1 (CB1R) availability.

Key facts

Study ID

NCT05683184

Run by

Yale University

People needed

30

Starts

2023-03-10

Expected to finish

2026-12-15

Last updated by the study team

2026-04-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Able to provide informed consent
• Male and female 18 years and older
• DSM-5 diagnosis of opioid use disorder (for OUD group)
• Physically healthy i.e., no clinically unstable medical conditions
• Written informed consent and have capacity to consent and comply with study procedures

You may not qualify if…

• Current neuro-psychiatric illness or severe systemic disease (opioid use disorder is permitted in the OUD group).
• Presence of ferromagnetic metal in the body or heart pacemaker
• Have had exposure to ionizing radiation that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits
• Are claustrophobic

Where it is running

• Connecticut Mental Health Center, Clinical Neuroscience Research Unit — New Haven, Connecticut, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.